PATENT Customer No. 22,852 Attorney Docket No. 06478.1494

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	Application of:	
Hube	rt METZNER et al.) Group Art Unit: Unassigned
Application No.: Unassigned) Examiner: Unassigned
Filed:	Herewith))
For:	Concentrate of a factor VIII:C- containing von Willebrand factor and the process relating thereto)))
P.O. 6	nissioner for Patents Box 1450 ndria, VA 22313-1450	
Cir.		

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits.

Copies of the listed documents, including any copending patent applications, are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

An English-language abstract for non-English document EP 0705846 A1 is enclosed.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L. L. P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: September 22, 2003

By:

Sanya Sukduang

FINNEGAN HENDERSON FARABOW GARRETT & DUNNERLLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06478.1494	Appln. No.	Unassigned
Applicant	METZNER et al.		
Filing Date	September 22, 2003	Group:	Unassigned

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

	FOREIGN PATE	ENT DOCUMENT	S		· · · · · · · · · · · · · · · · · · ·
Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
0 705 846 A1	09/29/1995	EP			Yes (Abstract)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.).				
	MANNUCCI, P. M. et al., "Multicenter Comparison of von Willebrand Factor Multimer Sizing Techniques," <i>Thrombosis and Haemostasis</i> , 54(4): 873-876 (1985).			
	LOMBARDI, R. et al., "Electroblot and Immunoperoxidase Staining for Rapid Screening of the Abnormalities of the Multimeric Structure of von Willebrand Factor in von Willebrand's Disease," <i>Thrombosis and Haemostasis</i> , 55(2): 246-249 (1986).			
	BAILLOD, P. et al., "Multimeric Analysis of von Willebrand Factor by Vertical Sodium Dodecyl Sulphate Agarose Gel Electrophoresis, Vacuum Blotting Technology and Sensitive Visualization by Alkaline Phosphatase Anti-Alkaline Phosphatase Complex," <i>Thrombosis Research</i> , 66: 745-755 (1992).			
	GIRMA, J.P. et al., "Structure-Function Relationship of Human Von Willebrand Factor," <i>Blood</i> , 70(3): 605-611 (1987).			

Examiner		Date Considered
*Examiner:		not citation is in conformance with MPEP 609; draw line d not considered. Include copy of this form with next
Form PTO 14	49 Patent a	nd Trademark Office - U.S. Department of Commerce

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	06478.1494	Appln. No.	Unassigned	
Applicant	METZNER et al.			
Filing Date	September 22, 2003	Group:	Unassigned	

	FASS, D.N., "Factor VIII Structure and Function," Ann NY Acad. Sci., 614: 76-88 (1991).
	HAMER, R. J., "Factor VIII Binds to von Willebrand Factor Via Its M _r -80 000 Light Chain," <i>Eur. J. Biochem.</i> , 166: 37-43 (1987).
	CORNU, P. et al., "Transfusion Studies in von Willebrand's Disease: Effect on Bleeding Time and Factor VIII," <i>Brit. J. Haemat</i> , 9: 189-202 (1963).
	WEISS, H. J. et al., "Stabilization of Factor VIII in Plasma by the von Willebrand Factor," The Journal of Clinical Investigation, 60: 390-404 (1977).
	JAFFE, E. A. et al., "Synthesis of von Willebrand Factor by Cultured Human Endothelial Cells," Proc. Nat. Acad. Sci, 71(5): 1906-1909 (1974).
	NACHMAN, R. et al., "Synthesis of Factor VIII Antigen by Cultured Guinea Pig Megakaryocytes," <i>The Journal of Clinical Investigation</i> , 60: 914-921 (1977).
	SCOTT, J. P. et al., "Therapy of von Willebrand Disease," Seminars in Thrombosis and Hemostasis, 19(1): 37-47 (1993).
	PERRET, B.A. et al., "Isolation of Small Molecular Forms of Factor VIII/von Willebrand Factor from Plasma," <i>Haemostasis</i> , 14: 289-295 (1984).
	KASPER, C.K. et.al.; "A More Uniform Measurement of Factor VIII Inhibitors," <i>Thrombos. Diathes. Haemorrh.</i> , 34: 869-872 (1975).
	BEHRMANN, M. et al., "Von Willebrand Factor Modulates Factor VIII Immunogenicity: Comparative Study of Different Factor VIII Concentrates in a Haemophilia A Mouse Model," <i>Thromb Haemost</i> , 88: 221-229 (2002).
·	

Examiner		Date Considered
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449		Patent and Trademark Office - U.S. Department of Commerce